000181117 001__ 181117
000181117 005__ 20240229145640.0
000181117 0247_ $$2doi$$a10.3390/cells11152462
000181117 0247_ $$2pmid$$apmid:35954306
000181117 037__ $$aDKFZ-2022-01786
000181117 041__ $$aEnglish
000181117 082__ $$a570
000181117 1001_ $$0P:(DE-He78)43ea0369702f56d45fa4a32df9f49aca$$aRaut, Janhavi$$b0$$eFirst author$$udkfz
000181117 245__ $$aAssessment of a Serum Microrna Risk Score for Colorectal Cancer among Participants of Screening Colonoscopy at Various Stages of Colorectal Carcinogenesis.
000181117 260__ $$aBasel$$bMDPI$$c2022
000181117 3367_ $$2DRIVER$$aarticle
000181117 3367_ $$2DataCite$$aOutput Types/Journal article
000181117 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660554892_9214
000181117 3367_ $$2BibTeX$$aARTICLE
000181117 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181117 3367_ $$00$$2EndNote$$aJournal Article
000181117 500__ $$a#EA:C070#EA:C120#LA:C070#LA:C120#
000181117 520__ $$aWe recently derived and validated a serum-based microRNA risk score (miR-score) which predicted colorectal cancer (CRC) occurrence with very high accuracy within 14 years of follow-up in a large population-based cohort. Here, we aimed to assess and compare the distribution of the miR-score among participants of screening colonoscopy at various stages of colorectal carcinogenesis. MicroRNAs (miRNAs) were profiled by quantitative-real-time-polymerase-chain-reaction in the serum samples of screening colonoscopy participants with CRC (n = 52), advanced colorectal adenoma (AA, n = 100), non-advanced colorectal adenoma (NAA, n = 88), and participants free of colorectal neoplasms (n = 173). The mean values of the miR-score were compared between groups by the Mann-Whitney U test. The associations of the miR-score with risk for colorectal neoplasms were evaluated using logistic regression analyses. MicroRNA risk scores were significantly higher among participants with AA than among those with NAA (p = 0.027) and those with CRC (p = 0.014), whereas no statistically significant difference was seen between those with NAA and those with no colorectal neoplasms (p = 0.127). When comparing adjacent groups, miR-scores were inversely associated with CRC versus AA and positively associated with AA versus NAA [odds ratio (OR), 0.37 (95% confidence interval (CI), 0.16-0.86) and OR, 2.22 (95% CI, 1.06-4.64) for the top versus bottom tertiles, respectively]. Our results are consistent with the hypothesis that a high miR-score may be indicative of an increased CRC risk by an increased tendency of progression from non-advanced to advanced colorectal neoplasms, along with a change of the miR-patterns after CRC manifestation.
000181117 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000181117 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181117 650_7 $$2Other$$ablood-based
000181117 650_7 $$2Other$$acolorectal cancer
000181117 650_7 $$2Other$$amiRNA
000181117 650_7 $$2Other$$arisk stratification
000181117 650_7 $$2Other$$arisk-adapted screening
000181117 7001_ $$0P:(DE-He78)ac7aed57f26354e8a484b5d257f7bada$$aBhardwaj, Megha$$b1$$udkfz
000181117 7001_ $$0P:(DE-He78)20dc4ad11ff465acf5b99f1e679e10b7$$aNiedermaier, Tobias$$b2$$udkfz
000181117 7001_ $$0P:(DE-He78)b97fc5666ea8f9db9ef499de6b2397cf$$aMiah, Kaya$$b3$$udkfz
000181117 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b4$$udkfz
000181117 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$eLast author$$udkfz
000181117 773__ $$0PERI:(DE-600)2661518-6$$a10.3390/cells11152462$$gVol. 11, no. 15, p. 2462 -$$n15$$p2462$$tCells$$v11$$x2073-4409$$y2022
000181117 909CO $$ooai:inrepo02.dkfz.de:181117$$pVDB
000181117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)43ea0369702f56d45fa4a32df9f49aca$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000181117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ac7aed57f26354e8a484b5d257f7bada$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000181117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)20dc4ad11ff465acf5b99f1e679e10b7$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000181117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b97fc5666ea8f9db9ef499de6b2397cf$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000181117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000181117 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000181117 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000181117 9141_ $$y2022
000181117 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000181117 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000181117 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000181117 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000181117 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000181117 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000181117 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELLS-BASEL : 2021$$d2022-11-30
000181117 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000181117 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000181117 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-07T08:42:17Z
000181117 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-07T08:42:17Z
000181117 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-01-07T08:42:17Z
000181117 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-30
000181117 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-30
000181117 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000181117 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000181117 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000181117 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCELLS-BASEL : 2021$$d2022-11-30
000181117 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000181117 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000181117 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000181117 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000181117 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x2
000181117 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000181117 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000181117 9200_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000181117 980__ $$ajournal
000181117 980__ $$aVDB
000181117 980__ $$aI:(DE-He78)C070-20160331
000181117 980__ $$aI:(DE-He78)C120-20160331
000181117 980__ $$aI:(DE-He78)C060-20160331
000181117 980__ $$aI:(DE-He78)HD01-20160331
000181117 980__ $$aUNRESTRICTED